Skip to main content
SpringerLink
Log in

Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

The CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen is known to be an effective primary therapy in patients with newly diagnosed multiple myeloma (MM). However, stem cell yields after CTD remain inconsistent. The aim of the present study is to identify the influence of the CTD regimen on the outcome of peripheral blood stem cell (PBSC) collection. Fifty-four patients received four cycles of CTD, and PBSCs were mobilized with cyclophosphamide and G-CSF or with G-CSF alone. Each patient from whom ≤4.0 × 106 CD34+ cells/kg were collected received a second mobilization course. The median duration from the start of a CTD regimen to the first collection was 4.3 months. Forty-eight patients were mobilized with cyclophosphamide followed by G-CSF, and six patients were mobilized with G-CSF alone. The median day of apheresis was day 3 (range day 2–day 5). The overall response rate at mobilization was 96.3 %, including 11.1 % complete response, 22.2 % very good partial response, and 63.0 % partial response. The median number of harvested CD34+ cells was 12.8 × 106 cells/kg. At the second mobilization, 88.9 % of patients reached the minimal stem cell collection target of ≥2.0 × 106 cells/kg, and 75.9 % of patients achieved the collection target of ≥4.0 × 106 cells/kg. CTD within four cycles is an effective primary therapy in patients with newly diagnosed MM and only minimally affects subsequent PBSC collection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Bjorkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol. 2007;25:1993–9.

    Article  PubMed  Google Scholar 

  2. Brenner H, Gondos A, Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood. 2008;111:2521–6.

    Article  PubMed  CAS  Google Scholar 

  3. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20.

    Article  PubMed  CAS  Google Scholar 

  4. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046–60.

    Article  PubMed  CAS  Google Scholar 

  5. Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009;114:1729–35.

    Article  PubMed  CAS  Google Scholar 

  6. Kim JE, Yoo C, Kim S, Lee DH, Kim SW, Lee JS, et al. Optimal timing of G-CSF administration for effective autologous stem cell collection. Bone Marrow Transplant. 2011;46:806–12.

    Article  PubMed  CAS  Google Scholar 

  7. Cavallo F, Bringhen S, Milone G, Ben-Yehuda D, Nagler A, Calabrese E, et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia. 2011;25:1627–31.

    Article  PubMed  CAS  Google Scholar 

  8. Kumar S, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Gastineau DA, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia. 2007;21:2035–42.

    Article  PubMed  CAS  Google Scholar 

  9. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant. 2009;15:718–23.

    Article  PubMed  Google Scholar 

  10. Koh KR, Janz M, Mapara MY, Lemke B, Stirling D, Dorken B, et al. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood. 2005;105:3833–40.

    Article  PubMed  CAS  Google Scholar 

  11. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–6.

    Article  PubMed  CAS  Google Scholar 

  12. Cavo M, Zamagni E, Tosi P, Tacchetti P, Cellini C, Cangini D, et al. Superiority of thalidomide and dexamethasone over vincristine–doxorubicin–dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106:35–9.

    Article  PubMed  CAS  Google Scholar 

  13. Sidra G, Williams CD, Russell NH, Zaman S, Myers B, Byrne JL. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica. 2006;91:862–3.

    PubMed  CAS  Google Scholar 

  14. Yang DH, Kim YK, Sohn SK, Chung JS, Joo YD, Lee JH, et al. Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study. Clin Lymphoma Myeloma Leuk. 2010;10:62–7.

    Article  PubMed  CAS  Google Scholar 

  15. Morgan GJ, Davies FE, Gregory WM, Russell NH, Bell SE, Szubert AJ, et al. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation. Blood. 2011;118:1231–8.

    Article  PubMed  CAS  Google Scholar 

  16. Morgan GJ, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro Coy N, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012;97(3):442–50.

    Article  PubMed  CAS  Google Scholar 

  17. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet. 2009;374:324–39.

    Article  PubMed  Google Scholar 

  18. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Eng J Med. 1996;335:91–7.

    Article  CAS  Google Scholar 

  19. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol. 2007;25:2434–41.

    Article  PubMed  Google Scholar 

  20. Breitkreutz I, Lokhorst HM, Raab MS, Holt B, Cremer FW, Herrmann D, et al. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield. Leukemia. 2007;21:1294–9.

    Article  PubMed  CAS  Google Scholar 

  21. Auner HW, Mazzarella L, Cook L, Szydlo R, Saltarelli F, Pavlu J, et al. High rate of stem cell mobilization failure after thalidomide and oral cyclophosphamide induction therapy for multiple myeloma. Bone Marrow Transplant. 2011;46:364–7.

    Article  PubMed  CAS  Google Scholar 

  22. Lefrere F, Zohar S, Ghez D, Delarue R, Audat F, Suarez F, et al. The VAD chemotherapy regimen plus a G-CSF dose of 10 µg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 µg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients. Bone Marrow Transplant. 2006;37:725–9.

    Article  PubMed  CAS  Google Scholar 

  23. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A, et al. Mobilization of CD34+ cells in elderly patients (≥70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol. 2003;120:413–23.

    Article  PubMed  Google Scholar 

  24. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–8.

    Article  PubMed  CAS  Google Scholar 

  25. Sharabi A, Haran-Ghera N. Immune recovery after cyclophosphamide treatment in multiple myeloma: implication for maintenance immunotherapy. Bone Marrow Res. 2011;2011:269519.

    PubMed  Google Scholar 

  26. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641–8.

    Article  PubMed  CAS  Google Scholar 

  27. Gertz MA, Kumar SK, Lacy MQ, Dispenzieri A, Hayman SR, Buadi FK, et al. Comparison of high-dose CY and growth factor with growth factor alone for mobilization of stem cells for transplantation in patients with multiple myeloma. Bone Marrow Transplant. 2009;43:619–25.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, 322 Seoyangro, Hwasun, Jeollanamdo, 519-763, Republic of Korea

    Sung-Hoon Jung, Hyungchul Park, Jae-Sook Ahn, Deok-Hwan Yang, Mi-Young Kim, Yeo-Kyeoung Kim, Hyeoung-Joon Kim & Je-Jung Lee

  2. The Brain Korea 21 Project, Center for Biomedical Human Resources at Chonnam National University, Gwangju, Republic of Korea

    Je-Jung Lee

Authors
  1. Sung-Hoon Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyungchul Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jae-Sook Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Deok-Hwan Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mi-Young Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yeo-Kyeoung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hyeoung-Joon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Je-Jung Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Je-Jung Lee.

About this article

Cite this article

Jung, SH., Park, H., Ahn, JS. et al. Efficacy of stem cell mobilization in patients with newly diagnosed multiple myeloma after a CTD (cyclophosphamide, thalidomide, and dexamethasone) regimen. Int J Hematol 97, 92–97 (2013). https://doi.org/10.1007/s12185-012-1237-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-012-1237-0

Keywords

Search

Navigation